[1] Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest,2009,119:1322-1334.
[2] Aeberli I, Hochuli M, Gerber PA, et al. Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial. Diabetes Care,2013,36:150-156.
[3] Geidl-Flueck B, Hochuli M, Nemeth A, et al. Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. J Hepatol,2021,75:46-54.
[4] Kohlmeier M. Nutrient Metabolism. London: Academic Press, 2003:193-210.
[5] Jang C, Hui S, Lu W, et al. The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. Cell Metab,2018,27:351-361 e3.
[6] Softic S, Cohen DE, Kahn CR. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig Dis Sci,2016,61:1282-1293.
[7] Lim JS, Mietus-Snyder M, Valente A, et al. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol,2010,7:251-264.
[8] Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol,2008,48:983-992.
[9] Spruss A, Kanuri G, Stahl C, et al. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest,2012,92:1020-1032.
[10] Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr,2008,138:1452-1455.
[11] Todoric J, Di Caro G, Reibe S, et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab,2020,2:1034-1045.
[12] Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49:1877-1887.
[13] Lanaspa MA, Andres-Hernando A, Orlicky DJ, et al. Ketohexokinase C blockade ameliorates fructose-induced metabolic dysfunction in fructose-sensitive mice. J Clin Invest,2018,128:2226-2238.
[14] Cho YE, Kim DK, Seo W, et al. Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress. Hepatology, 2021,73:2180-2195.
[15] Volynets V, Louis S, Pretz D, et al. Intestinal Barrier Function and the Gut Microbiome Are Differentially Affected in Mice Fed a Western-Style Diet or Drinking Water Supplemented with Fructose. J Nutr, 2017,147:770-780.
[16] Beisner J, Gonzalez-Granda A, Basrai M, et al. Fructose-Induced Intestinal Microbiota Shift Following Two Types of Short-Term High-Fructose Dietary Phases. Nutrients,2020,12:3444.
[17] Zhao S, Jang C, Liu J, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature,2020,579:586-591.
[18] Han S, Van Treuren W, Fischer CR, et al. A metabolomics pipeline for the mechanistic interrogation of the gut microbiome. Nature,2021,595:415-420.
[19] Tan R, Dong H, Chen Z, et al. Intestinal Microbiota Mediates High-Fructose and High-Fat Diets to Induce Chronic Intestinal Inflammation. Front Cell Infect Microbiol,2021,11:654074.
[20] Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol,2019,71:1216-1228. |
